ESPR Q3 2023 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$34M+79.0% YoY

Gross Profit

$21M60.6% margin

Operating Income

-$28M-81.1% margin

Net Income

-$41M-121.4% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+31.7%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$221M

Total Liabilities

$631M

Stockholders' Equity

-$410M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$19M	+79.0%
Gross Profit	$21M	$12M	+65.1%
Operating Income	-$28M	-$42M	+33.9%
Net Income	-$41M	-$55M	+25.2%

Revenue Segments

Product

$20M60%

Collaboration Revenue

$14M40%